Skip to main content

Lupus

      RT @Yuz6Yusof: #EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK s

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 4 months ago
      #EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
      The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. We now have three licensed targeted therapies (belimumab and voclosporin in active lupus nephritis and anifrolumab in non-renal SLE) over the last 3 years compared to one therapy (belimumab in non-renal SLE) in the previous 50 years. What are other promising therapies on the horizon? 
      RT @bella_mehta: Medication adherence in #lupus - assessed using Optum administrative database 14 yrs. 12510 pts. Median

      Bella Mehta bella_mehta

      2 years 4 months ago
      Medication adherence in #lupus - assessed using Optum administrative database 14 yrs. 12510 pts. Median copays were less than $ 10. Black and hispanics had significantly lower odds of adherence after adjusting for several SDOH! @rheumnow #EULAR2023 abst#AB0579 https://t.co/pO5tjzTPbz
      RT @bella_mehta: Recruitment in clinical trials is tough in #lupus and #CTD. A #EULAR2023 study of 49 trials, 1909 recor

      Bella Mehta bella_mehta

      2 years 4 months ago
      Recruitment in clinical trials is tough in #lupus and #CTD. A #EULAR2023 study of 49 trials, 1909 records- in an unselected, real world cohort of #CTD pts, upto 50% would be excluded due to classification criteria or overlapping features etc! Abst#op0013 @RheumNow https://t.co/X3YuvgSVzo
      Baricitinib in Lupus Nephritis
      RT @Yuz6Yusof: #EULAR2023 #OP0052 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 4 months ago
      #EULAR2023 #OP0052 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/vylWCf0XNy
      RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All conten

      Dr. John Cush RheumNow

      2 years 4 months ago
      RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
      RT @Yuz6Yusof: #EULAR2023 #OP0053 Baricitinib in non-renal #lupus were inconclusive. How about Renal #SLE?An RCT showed

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 4 months ago
      #EULAR2023 #OP0053 Baricitinib in non-renal #lupus were inconclusive. How about Renal #SLE?An RCT showed primary endpoint (=>50% reduction in proteinuria) was met more in Bari vs Cyclo at Wks12 & 24. Intriguing but need longer-term, composite endpoint and larger size! @RheumNow https://t.co/z3YJog6gTy
      RT @Yuz6Yusof: #EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose?

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 4 months ago
      #EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/bBtBm1olcr
      RT @synovialjoints: Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of

      Dr. Antoni Chan synovialjoints

      2 years 4 months ago
      Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
      RT @Yuz6Yusof: #EULAR2023 #OP0051 4-year Pooled Analyses of 3 x Anifrolumab RCTs in #lupus (inc. LTE) showed:

      - LLDAS

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 4 months ago
      #EULAR2023 #OP0051 4-year Pooled Analyses of 3 x Anifrolumab RCTs in #lupus (inc. LTE) showed: - LLDAS was attained earlier & more cumulative time was spent in LLDAS in anifrolumab compared to placebo groups Assuring longer-term data *sorry photos weren’t permitted @RheumNow
      RT @drdavidliew: Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the

      David Liew drdavidliew

      2 years 4 months ago
      Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
      RT @Yuz6Yusof: #EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Activ

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 4 months ago
      #EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Active Clinically Quiescent? A cohort study in Asia showed: - Tapering was NOT associated with subsequent flare - Tapering reduced damage in those on =>5mg/day @RheumNow https://t.co/Q6GiaSCgV6
      RT @synovialjoints: Improving access and education to SLE patients using the Lupus 100 project which uses native languag

      Dr. Antoni Chan synovialjoints

      2 years 4 months ago
      Improving access and education to SLE patients using the Lupus 100 project which uses native language covering 95% of the European population to provide high quality and accurate information for patients by Zoe Karakla-Mitsakou Abst#OP0004 @RheumNow https://t.co/mWRiZt7uGy
      RT @drdavidliew: Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid m

      David Liew drdavidliew

      2 years 4 months ago
      Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid misinformation and check it out in your language at https://t.co/R2ydvDasFY Congratulations @LupusEurope! #EULAR2023 OP0004 @RheumNow https://t.co/S4sgy5dnro
      ×